Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
SGO 2024 Annual Meeting on Womens Cancer
2024 Multidisciplinary Head and Neck Cancers Symposium
2024 ASCO GU Cancers Symposium
2024 ASCO GI Cancers Symposium
2023 ASH
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
The ASCO Post Roundtable Series
present case-based, tumor-specific discussions on the latest developments in cancer care. Join key experts in oncology as they discuss the management of challenging clinical scenarios in oncology.
Optimizing Outcomes for Patients With Locally Advanced and Metastatic NSCLC
Targeting Endocrine Resistance in HR-Positive/HER2-Negative Metastatic Breast Cancer
Clinical Considerations in the Treatment of Metastatic ROS1 Fusion–Positive NSCLC
New Directions in Nonmetastatic Non–Small Cell Lung Cancer
Evolving Skin Cancer Management
Updates in Early-Stage Breast Cancer
Ovarian Function Suppression in Breast Cancer
New Directions in Metastatic Colorectal Cancer
Novel Therapies for Advanced Breast Cancer
Clinical Advances in Diffuse Large B-Cell Lymphoma
Treatment Considerations in Renal Cell Carcinoma
Updates in Myeloproliferative Neoplasms
Clinical Advances in Mantle Cell Lymphoma
Advances in Follicular Lymphoma
Novel Hormonal Therapies for Prostate Cancer
The Evolving Treatment Landscape for Colorectal Cancer
Clinical Considerations in Chronic Graft-vs-Host Disease
Updates in Melanoma
Updates in Hepatobiliary Cancer
Updates in Renal Cell Carcinoma
Updates in Colorectal Cancer
Updates in HER2-Positive Breast Cancer
Updates in Lymphoma
Updates in Prostate Cancer (1)
Updates in Acute Myeloid Leukemia
Updates in Lung Cancer
Updates in Breast Cancer
Updates in Prostate Cancer
Updates in Gynecologic Oncology
Appropriate Management of Challenging Cases in Lung Cancer
Appropriate Management of Challenging Cases in Myeloma and Lymphoma
Advertisement
Advertisement
Mar
19
Today In Oncology
FDA Grants Accelerated Approval to Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma
Durvalumab-Based Regimens Improve Response Over Chemotherapy Alone in pMMR Advanced Endometrial Cancer
Zanubrutinib vs Acalabrutinib in Relapsed or Refractory CLL New Efficacy Analysis
Localized or Advanced Prostate Cancer Short- or Longer-Term Relugolix Plus Radiotherapy
ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer
View More
Advertisement